Benefits
Improved glucose and metabolic markers
Akkermansia muciniphila supplementation improved insulin sensitivity and metabolic markers in a Nature Medicine RCT; NūGensia's manufacturer trial in prediabetic adults reports lower fasting and post-meal glucose and HbA1c. Strong class evidence.
Weight and waist support
The Akkermansia trials reported modest reductions in body weight, fat mass and waist circumference, consistent with NūGensia's positioning.
Gut-barrier support
Akkermansia is a mucin-associated commensal that strengthens the gut barrier, a mechanism linking it to metabolic health.
Mechanism of action
Gut-barrier and mucin layer support
Akkermansia muciniphila lives in and reinforces the intestinal mucus layer, reducing 'leaky gut' and the low-grade inflammation that drives metabolic dysfunction.
Metabolic endotoxemia reduction
By tightening the gut barrier, Akkermansia lowers circulating bacterial endotoxin, improving insulin sensitivity and metabolic markers.
Clinical trials
Depommier 2019 proof-of-concept RCT (Nature Medicine) and a 2026 Nature Medicine weight-loss study.
Overweight/obese adults with metabolic risk
Supplementation (live or pasteurized) improved insulin sensitivity and metabolic markers and supported weight loss versus placebo — landmark evidence for the class.
Randomized, placebo-controlled, n=60 prediabetic adults, ~10 billion CFU/day for 60 days. Published in a non-PubMed-indexed journal.
Adults with prediabetes (31–60 y)
Manufacturer reports lower fasting/postprandial glucose, HbA1c and triglycerides, with reduced weight/BMI/waist. Treat as manufacturer evidence supported by the class data.